105 related articles for article (PubMed ID: 17404720)
1. Modelling the influence of MDR1 polymorphism on digoxin pharmacokinetic parameters.
Comets E; Verstuyft C; Lavielle M; Jaillon P; Becquemont L; Mentré F
Eur J Clin Pharmacol; 2007 May; 63(5):437-49. PubMed ID: 17404720
[TBL] [Abstract][Full Text] [Related]
2. Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition.
Verstuyft C; Strabach S; El-Morabet H; Kerb R; Brinkmann U; Dubert L; Jaillon P; Funck-Brentano C; Trugnan G; Becquemont L
Clin Pharmacol Ther; 2003 Jan; 73(1):51-60. PubMed ID: 12545143
[TBL] [Abstract][Full Text] [Related]
3. Effect of grapefruit juice on digoxin pharmacokinetics in humans.
Becquemont L; Verstuyft C; Kerb R; Brinkmann U; Lebot M; Jaillon P; Funck-Brentano C
Clin Pharmacol Ther; 2001 Oct; 70(4):311-6. PubMed ID: 11673746
[TBL] [Abstract][Full Text] [Related]
4. A variant 2677A allele of the MDR1 gene affects fexofenadine disposition.
Yi SY; Hong KS; Lim HS; Chung JY; Oh DS; Kim JR; Jung HR; Cho JY; Yu KS; Jang IJ; Shin SG
Clin Pharmacol Ther; 2004 Nov; 76(5):418-27. PubMed ID: 15536457
[TBL] [Abstract][Full Text] [Related]
5. Digoxin pharmacokinetics and MDR1 genetic polymorphisms.
Verstuyft C; Schwab M; Schaeffeler E; Kerb R; Brinkmann U; Jaillon P; Funck-Brentano C; Becquemont L
Eur J Clin Pharmacol; 2003 Apr; 58(12):809-12. PubMed ID: 12698307
[TBL] [Abstract][Full Text] [Related]
6. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene.
Johne A; Köpke K; Gerloff T; Mai I; Rietbrock S; Meisel C; Hoffmeyer S; Kerb R; Fromm MF; Brinkmann U; Eichelbaum M; Brockmöller J; Cascorbi I; Roots I
Clin Pharmacol Ther; 2002 Nov; 72(5):584-94. PubMed ID: 12426522
[TBL] [Abstract][Full Text] [Related]
7. Human intestinal P-glycoprotein activity estimated by the model substrate digoxin.
Larsen UL; Hyldahl Olesen L; Guldborg Nyvold C; Eriksen J; Jakobsen P; Østergaard M; Autrup H; Andersen V
Scand J Clin Lab Invest; 2007; 67(2):123-34. PubMed ID: 17365992
[TBL] [Abstract][Full Text] [Related]
8. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol.
Siegmund W; Ludwig K; Giessmann T; Dazert P; Schroeder E; Sperker B; Warzok R; Kroemer HK; Cascorbi I
Clin Pharmacol Ther; 2002 Nov; 72(5):572-83. PubMed ID: 12426521
[TBL] [Abstract][Full Text] [Related]
9. Impact of MDR1 haplotypes derived from C1236T, G2677T/A and C3435T on the pharmacokinetics of single-dose oral digoxin in healthy Chinese volunteers.
Xu P; Jiang ZP; Zhang BK; Tu JY; Li HD
Pharmacology; 2008; 82(3):221-7. PubMed ID: 18810246
[TBL] [Abstract][Full Text] [Related]
10. MDR1 C3435T polymorphism in patients with breast cancer.
Turgut S; Yaren A; Kursunluoglu R; Turgut G
Arch Med Res; 2007 Jul; 38(5):539-44. PubMed ID: 17560460
[TBL] [Abstract][Full Text] [Related]
11. Comparison of model-based tests and selection strategies to detect genetic polymorphisms influencing pharmacokinetic parameters.
Bertrand J; Comets E; Mentre F
J Biopharm Stat; 2008; 18(6):1084-102. PubMed ID: 18991109
[TBL] [Abstract][Full Text] [Related]
12. No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects.
Pauli-Magnus C; Feiner J; Brett C; Lin E; Kroetz DL
Clin Pharmacol Ther; 2003 Nov; 74(5):487-98. PubMed ID: 14586389
[TBL] [Abstract][Full Text] [Related]
13. [Effect of MDR1 polymorphic expression on oral disposition of cyclosporine A].
Jiao Z; Liang HQ; Ding JJ; Li ZD; Shi XJ; Zhong MK
Yao Xue Xue Bao; 2004 Dec; 39(12):971-4. PubMed ID: 15813023
[TBL] [Abstract][Full Text] [Related]
14. Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer.
Kafka A; Sauer G; Jaeger C; Grundmann R; Kreienberg R; Zeillinger R; Deissler H
Int J Oncol; 2003 May; 22(5):1117-21. PubMed ID: 12684679
[TBL] [Abstract][Full Text] [Related]
15. Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients.
Solas C; Simon N; Drogoul MP; Quaranta S; Frixon-Marin V; Bourgarel-Rey V; Brunet C; Gastaut JA; Durand A; Lacarelle B; Poizot-Martin I
Br J Clin Pharmacol; 2007 Sep; 64(3):353-62. PubMed ID: 17517050
[TBL] [Abstract][Full Text] [Related]
16. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects.
Sakaeda T; Nakamura T; Horinouchi M; Kakumoto M; Ohmoto N; Sakai T; Morita Y; Tamura T; Aoyama N; Hirai M; Kasuga M; Okumura K
Pharm Res; 2001 Oct; 18(10):1400-4. PubMed ID: 11697464
[TBL] [Abstract][Full Text] [Related]
17. MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males.
Gerloff T; Schaefer M; Johne A; Oselin K; Meisel C; Cascorbi I; Roots I
Br J Clin Pharmacol; 2002 Dec; 54(6):610-6. PubMed ID: 12492608
[TBL] [Abstract][Full Text] [Related]
18. ABCB1 C3435T genetic polymorphism on population pharmacokinetics of methotrexate after hematopoietic stem cell transplantation in Korean patients: a prospective analysis.
Kim IW; Yun HY; Choi B; Han N; Park SY; Lee ES; Oh JM
Clin Ther; 2012 Aug; 34(8):1816-26. PubMed ID: 22796246
[TBL] [Abstract][Full Text] [Related]
19. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein.
Kurata Y; Ieiri I; Kimura M; Morita T; Irie S; Urae A; Ohdo S; Ohtani H; Sawada Y; Higuchi S; Otsubo K
Clin Pharmacol Ther; 2002 Aug; 72(2):209-19. PubMed ID: 12189368
[TBL] [Abstract][Full Text] [Related]
20. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation.
Anglicheau D; Thervet E; Etienne I; Hurault De Ligny B; Le Meur Y; Touchard G; Büchler M; Laurent-Puig P; Tregouet D; Beaune P; Daly A; Legendre C; Marquet P
Clin Pharmacol Ther; 2004 May; 75(5):422-33. PubMed ID: 15116055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
